NeuroFrontiers
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
76-90 of 394

Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiersMultiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care

Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiersAdvancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers

Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiersUnderstanding Accelerated Biological Aging in Pediatric MS

Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiersMultiple Sclerosis Without Borders: Taking a Global View

Optimizing Vitamin D Supplementation in MS Care
NeuroFrontiersOptimizing Vitamin D Supplementation in MS Care

Iron Deposition and Cognitive Fatigue in Multiple Sclerosis
NeuroFrontiersIron Deposition and Cognitive Fatigue in Multiple Sclerosis
- advertisement

Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
NeuroFrontiersVitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS

The Role of Neurofilament Light Chain in MS Management
NeuroFrontiersThe Role of Neurofilament Light Chain in MS Management

Parkinson’s Research in Focus: Translating Science Into Clinical Progress
NeuroFrontiersParkinson’s Research in Focus: Translating Science Into Clinical Progress

Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care
NeuroFrontiersBridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups
- advertisement

Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
NeuroFrontiersIndividualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT

Aducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
NeuroFrontiersAducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline

Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
NeuroFrontiersEvaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers






































